Sign in

You're signed outSign in or to get full access.

Yiyi Chen

Research Analyst at Mizuho Securities

Yiyi Chen is a Research Analyst at Mizuho Securities, specializing in equity research with a focus on biotechnology and pharmaceutical companies. She has engaged with firms such as Alkermes through earnings call questions, though specific performance metrics like success rates or rankings on platforms such as TipRanks are not publicly detailed in available sources. Chen's career includes her role as an Equity Research Associate at Mizuho Securities USA LLC from 2018 to 2020, preceded by experience as an Associate at Deloitte; professional credentials such as FINRA registrations or securities licenses are not specified in records.

Yiyi Chen's questions to Alkermes (ALKS) leadership

Question · Q4 2025

Yiyi Chen asked about Alkermes' strategy for VIVITROL given potential generic entry in 2027, and whether Teva has the capability to manufacture generics.

Answer

Todd Nichols, Chief Commercial Officer of Alkermes, stated plans to continue VIVITROL's growth in 2026 and prepare for multiple scenarios in 2027. He noted that VIVITROL is difficult to commercialize and manufacture, and they will monitor Teva's capabilities and market supply, prepared to compete or adjust spending.

Ask follow-up questions

Fintool

Fintool can predict Alkermes logo ALKS's earnings beat/miss a week before the call

Question · Q4 2025

Yiyi Chen asked about the dynamics of potential generic entry for VIVITROL in 2027 and whether Teva has the capability to manufacture generics at this point.

Answer

Todd Nichols, Chief Commercial Officer, stated that Alkermes plans to continue VIVITROL's growth through 2026 and is preparing for multiple scenarios in 2027. He emphasized that VIVITROL is a difficult product to commercialize and manufacture, and Alkermes will monitor generic capabilities and supply. They are prepared to compete and adjust spending if competition arises.

Ask follow-up questions

Fintool

Fintool can write a report on Alkermes logo ALKS's next earnings in your company's style and formatting